Associations Between Thiazolidinediones Use and Incidence of Rheumatoid Arthritis: A Retrospective Population‐Based Cohort Study
Main finding · Incident RAResult — go to the resultHazard ratio 0.72 95% CI 0.59–0.89Authors' conclusion
Use of TZDs is associated with a decreased risk of incident RA in patients with T2DM.
Study context
- Population
- Patients with type 2 diabetes mellitus (T2DM)
- Participants
- 14,892 vs 56,796
- Exposure
- Thiazolidinediones (TZDs) vs alpha glucosidase inhibitors in T2DM
- TZDsn = 14,892
- Alpha glucosidase inhibitors (AGIs)n = 56,796reference
- Outcome
- Incident rheumatoid arthritis (RA)
Methodological detailspopulation-based, new-user design, inverse probability of treatment weighted Cox model
- Population-based
- New-user design
- Inverse probability of treatment weighted Cox model
Main finding
As reported in the abstract
Hazard ratio
0.72
95% CI 0.59–0.89
By group
TZDsvs AGIs
HR 0.72 (95% CI 0.59–0.89)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Incident RA by cumulative TZD use 0.51 to 4.0 years | 0.55 (0.35–0.88) | |
| Incident RA by cumulative TZD use >4 years | 0.74 (0.57–0.98) | |
| 0.20.5125Hazard ratio (log scale) |
Subgroup and sensitivity analyses
- Consistent with the primary analysis
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Associations Between Thiazolidinediones Use and Incidence of Rheumatoid Arthritis: A Retrospective Population‐Based Cohort Study. Arthritis Care Res (Hoboken). Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →